Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by American International Group Inc.

American International Group Inc. increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) by 0.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 39,444 shares of the biopharmaceutical company’s stock after acquiring an additional 41 shares during the quarter. American International Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $34,643,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of REGN. Fiera Capital Corp raised its holdings in Regeneron Pharmaceuticals by 2.4% in the 3rd quarter. Fiera Capital Corp now owns 649 shares of the biopharmaceutical company’s stock valued at $534,000 after buying an additional 15 shares during the period. Catalyst Capital Advisors LLC raised its holdings in Regeneron Pharmaceuticals by 35.6% in the 3rd quarter. Catalyst Capital Advisors LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 21 shares during the period. Aviva PLC raised its holdings in Regeneron Pharmaceuticals by 51.2% in the 3rd quarter. Aviva PLC now owns 44,892 shares of the biopharmaceutical company’s stock valued at $36,944,000 after buying an additional 15,207 shares during the period. Rafferty Asset Management LLC increased its stake in Regeneron Pharmaceuticals by 4.6% during the third quarter. Rafferty Asset Management LLC now owns 32,055 shares of the biopharmaceutical company’s stock worth $26,380,000 after purchasing an additional 1,411 shares during the period. Finally, Rhenman & Partners Asset Management AB increased its stake in Regeneron Pharmaceuticals by 14.3% during the third quarter. Rhenman & Partners Asset Management AB now owns 40,000 shares of the biopharmaceutical company’s stock worth $32,918,000 after purchasing an additional 5,000 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

REGN stock traded up $9.97 during trading on Friday, reaching $1,036.52. 353,915 shares of the company were exchanged, compared to its average volume of 364,879. Regeneron Pharmaceuticals, Inc. has a 52-week low of $684.80 and a 52-week high of $1,042.66. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. The company has a market cap of $114.21 billion, a P/E ratio of 30.62, a PEG ratio of 2.14 and a beta of 0.13. The stock’s 50 day moving average price is $956.29 and its 200 day moving average price is $935.63.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The firm had revenue of $3.15 billion during the quarter, compared to analyst estimates of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Leonard S. Schleifer sold 25,000 shares of the business’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total value of $24,481,250.00. Following the completion of the transaction, the chief executive officer now directly owns 408,200 shares of the company’s stock, valued at $399,729,850. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CEO Leonard S. Schleifer sold 22,830 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, May 17th. The shares were sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the completion of the sale, the chief executive officer now directly owns 466,877 shares in the company, valued at $457,179,964.71. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Leonard S. Schleifer sold 25,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the sale, the chief executive officer now owns 408,200 shares of the company’s stock, valued at $399,729,850. The disclosure for this sale can be found here. Insiders sold a total of 59,680 shares of company stock worth $58,818,382 over the last 90 days. 7.48% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of recent research reports. Sanford C. Bernstein initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 price target on the stock. Morgan Stanley boosted their price target on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 13th. Royal Bank of Canada boosted their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,229.00 and gave the stock an “outperform” rating in a research note on Wednesday. Bank of America upped their target price on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research note on Friday, April 12th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $925.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, May 3rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $991.18.

Read Our Latest Stock Report on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Featured Articles

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.